STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems used to deliver the lenses into the eye. These lenses provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. The Company is a manufacturer of lenses used worldwide in corrective or refractive surgery. It sells its products in approximately 75 countries, with direct distribution in Japan, Germany, Spain, the United States, Canada, the United Kingdom, and Singapore, with a combination of direct distribution and independent distribution in China, Korea, India, France, Benelux, and Italy. The Company markets and sells ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. The Company’s EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The Company also markets and sells an ICL lens to treat hyperopia (farsightedness), which is called Visian ICL.
BörsenkürzelSTAA
Name des UnternehmensSTAAR Surgical Co
IPO-datumFeb 24, 1992
CEOMr. Stephen C. (Steve) Farrell, CPA
Anzahl der mitarbeiter1157
WertpapierartOrdinary Share
GeschäftsjahresendeFeb 24
Addresse1911 Walker Ave
StadtMONROVIA
BörseNASDAQ Global Market Consolidated
LandUnited States of America
Postleitzahl91016
Telefon16263037902
Websitehttps://www.staar.com/
BörsenkürzelSTAA
IPO-datumFeb 24, 1992
CEOMr. Stephen C. (Steve) Farrell, CPA
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten